nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2E1—Fingolimod—multiple sclerosis	0.189	0.223	CbGbCtD
Carbinoxamine—CYP2D6—Fingolimod—multiple sclerosis	0.0899	0.106	CbGbCtD
Carbinoxamine—CYP2E1—Mitoxantrone—multiple sclerosis	0.0887	0.105	CbGbCtD
Carbinoxamine—CYP3A4—Fingolimod—multiple sclerosis	0.0572	0.0675	CbGbCtD
Carbinoxamine—CYP2C19—Prednisone—multiple sclerosis	0.0462	0.0545	CbGbCtD
Carbinoxamine—CYP2E1—Dexamethasone—multiple sclerosis	0.046	0.0543	CbGbCtD
Carbinoxamine—CYP2B6—Dexamethasone—multiple sclerosis	0.0454	0.0536	CbGbCtD
Carbinoxamine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0368	0.0435	CbGbCtD
Carbinoxamine—CYP2C8—Dexamethasone—multiple sclerosis	0.0344	0.0406	CbGbCtD
Carbinoxamine—CYP2C19—Dexamethasone—multiple sclerosis	0.0288	0.034	CbGbCtD
Carbinoxamine—CYP3A4—Triamcinolone—multiple sclerosis	0.0279	0.033	CbGbCtD
Carbinoxamine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0269	0.0317	CbGbCtD
Carbinoxamine—CYP2C9—Dexamethasone—multiple sclerosis	0.024	0.0283	CbGbCtD
Carbinoxamine—CYP3A4—Betamethasone—multiple sclerosis	0.024	0.0283	CbGbCtD
Carbinoxamine—CYP3A4—Prednisolone—multiple sclerosis	0.0236	0.0279	CbGbCtD
Carbinoxamine—CYP3A4—Prednisone—multiple sclerosis	0.0223	0.0264	CbGbCtD
Carbinoxamine—CYP2D6—Dexamethasone—multiple sclerosis	0.0219	0.0259	CbGbCtD
Carbinoxamine—CYP3A4—Dexamethasone—multiple sclerosis	0.0139	0.0165	CbGbCtD
Carbinoxamine—Neuritis—Cladribine—multiple sclerosis	0.00314	0.0254	CcSEcCtD
Carbinoxamine—Wheezing—Cladribine—multiple sclerosis	0.00228	0.0184	CcSEcCtD
Carbinoxamine—Haemolytic anaemia—Cladribine—multiple sclerosis	0.00188	0.0152	CcSEcCtD
Carbinoxamine—Vision blurred—Fingolimod—multiple sclerosis	0.0017	0.0138	CcSEcCtD
Carbinoxamine—Neuritis—Prednisolone—multiple sclerosis	0.00169	0.0137	CcSEcCtD
Carbinoxamine—Palpitations—Fingolimod—multiple sclerosis	0.0016	0.0129	CcSEcCtD
Carbinoxamine—Neuritis—Triamcinolone—multiple sclerosis	0.00156	0.0126	CcSEcCtD
Carbinoxamine—Neuritis—Methylprednisolone—multiple sclerosis	0.00155	0.0126	CcSEcCtD
Carbinoxamine—Sweating increased—Cladribine—multiple sclerosis	0.00143	0.0116	CcSEcCtD
Carbinoxamine—Neuritis—Betamethasone—multiple sclerosis	0.00141	0.0114	CcSEcCtD
Carbinoxamine—Neuritis—Dexamethasone—multiple sclerosis	0.00141	0.0114	CcSEcCtD
Carbinoxamine—Hypotension—Fingolimod—multiple sclerosis	0.00138	0.0112	CcSEcCtD
Carbinoxamine—Paraesthesia—Fingolimod—multiple sclerosis	0.00132	0.0107	CcSEcCtD
Carbinoxamine—Fatigue—Fingolimod—multiple sclerosis	0.00127	0.0103	CcSEcCtD
Carbinoxamine—Neuritis—Prednisone—multiple sclerosis	0.00123	0.00995	CcSEcCtD
Carbinoxamine—Wheezing—Triamcinolone—multiple sclerosis	0.00113	0.00913	CcSEcCtD
Carbinoxamine—Euphoric mood—Prednisolone—multiple sclerosis	0.00109	0.00879	CcSEcCtD
Carbinoxamine—Asthenia—Fingolimod—multiple sclerosis	0.00106	0.00856	CcSEcCtD
Carbinoxamine—Chills—Cladribine—multiple sclerosis	0.00106	0.00854	CcSEcCtD
Carbinoxamine—Diarrhoea—Fingolimod—multiple sclerosis	0.00101	0.00817	CcSEcCtD
Carbinoxamine—Euphoric mood—Triamcinolone—multiple sclerosis	0.000999	0.00808	CcSEcCtD
Carbinoxamine—Euphoric mood—Methylprednisolone—multiple sclerosis	0.000996	0.00806	CcSEcCtD
Carbinoxamine—Agranulocytosis—Azathioprine—multiple sclerosis	0.000995	0.00805	CcSEcCtD
Carbinoxamine—Dizziness—Fingolimod—multiple sclerosis	0.000975	0.00789	CcSEcCtD
Carbinoxamine—Sweating increased—Mitoxantrone—multiple sclerosis	0.000941	0.00762	CcSEcCtD
Carbinoxamine—Headache—Fingolimod—multiple sclerosis	0.000924	0.00748	CcSEcCtD
Carbinoxamine—Euphoric mood—Betamethasone—multiple sclerosis	0.000906	0.00733	CcSEcCtD
Carbinoxamine—Euphoric mood—Dexamethasone—multiple sclerosis	0.000906	0.00733	CcSEcCtD
Carbinoxamine—Drowsiness—Mitoxantrone—multiple sclerosis	0.000862	0.00697	CcSEcCtD
Carbinoxamine—Chills—Azathioprine—multiple sclerosis	0.000859	0.00695	CcSEcCtD
Carbinoxamine—Confusional state—Cladribine—multiple sclerosis	0.000843	0.00682	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Cladribine—multiple sclerosis	0.000819	0.00662	CcSEcCtD
Carbinoxamine—Tachycardia—Cladribine—multiple sclerosis	0.000816	0.0066	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Cladribine—multiple sclerosis	0.000808	0.00654	CcSEcCtD
Carbinoxamine—Agranulocytosis—Mitoxantrone—multiple sclerosis	0.000804	0.00651	CcSEcCtD
Carbinoxamine—Irritability—Methylprednisolone—multiple sclerosis	0.000803	0.0065	CcSEcCtD
Carbinoxamine—Anorexia—Cladribine—multiple sclerosis	0.000797	0.00645	CcSEcCtD
Carbinoxamine—Euphoric mood—Prednisone—multiple sclerosis	0.000789	0.00638	CcSEcCtD
Carbinoxamine—Hypotension—Cladribine—multiple sclerosis	0.000781	0.00632	CcSEcCtD
Carbinoxamine—Sweating increased—Prednisolone—multiple sclerosis	0.000772	0.00625	CcSEcCtD
Carbinoxamine—Insomnia—Cladribine—multiple sclerosis	0.000756	0.00612	CcSEcCtD
Carbinoxamine—Paraesthesia—Cladribine—multiple sclerosis	0.000751	0.00608	CcSEcCtD
Carbinoxamine—Somnolence—Cladribine—multiple sclerosis	0.000743	0.00601	CcSEcCtD
Carbinoxamine—Irritability—Betamethasone—multiple sclerosis	0.000731	0.00591	CcSEcCtD
Carbinoxamine—Irritability—Dexamethasone—multiple sclerosis	0.000731	0.00591	CcSEcCtD
Carbinoxamine—Decreased appetite—Cladribine—multiple sclerosis	0.000727	0.00588	CcSEcCtD
Carbinoxamine—Fatigue—Cladribine—multiple sclerosis	0.000721	0.00583	CcSEcCtD
Carbinoxamine—Constipation—Cladribine—multiple sclerosis	0.000715	0.00579	CcSEcCtD
Carbinoxamine—Sweating increased—Triamcinolone—multiple sclerosis	0.00071	0.00575	CcSEcCtD
Carbinoxamine—Sweating increased—Methylprednisolone—multiple sclerosis	0.000709	0.00573	CcSEcCtD
Carbinoxamine—Chills—Mitoxantrone—multiple sclerosis	0.000694	0.00562	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Prednisolone—multiple sclerosis	0.000693	0.00561	CcSEcCtD
Carbinoxamine—Feeling abnormal—Cladribine—multiple sclerosis	0.000689	0.00558	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000666	0.00539	CcSEcCtD
Carbinoxamine—Urticaria—Cladribine—multiple sclerosis	0.000664	0.00537	CcSEcCtD
Carbinoxamine—Sweating increased—Betamethasone—multiple sclerosis	0.000645	0.00521	CcSEcCtD
Carbinoxamine—Sweating increased—Dexamethasone—multiple sclerosis	0.000645	0.00521	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Triamcinolone—multiple sclerosis	0.000637	0.00516	CcSEcCtD
Carbinoxamine—Irritability—Prednisone—multiple sclerosis	0.000636	0.00515	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Methylprednisolone—multiple sclerosis	0.000636	0.00515	CcSEcCtD
Carbinoxamine—Hypotension—Azathioprine—multiple sclerosis	0.000635	0.00514	CcSEcCtD
Carbinoxamine—Vision blurred—Mitoxantrone—multiple sclerosis	0.000635	0.00514	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—multiple sclerosis	0.000635	0.00513	CcSEcCtD
Carbinoxamine—Asthenia—Cladribine—multiple sclerosis	0.0006	0.00485	CcSEcCtD
Carbinoxamine—Convulsion—Mitoxantrone—multiple sclerosis	0.000583	0.00472	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Dexamethasone—multiple sclerosis	0.000578	0.00468	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Betamethasone—multiple sclerosis	0.000578	0.00468	CcSEcCtD
Carbinoxamine—Diarrhoea—Cladribine—multiple sclerosis	0.000572	0.00463	CcSEcCtD
Carbinoxamine—Sweating increased—Prednisone—multiple sclerosis	0.000561	0.00454	CcSEcCtD
Carbinoxamine—Feeling abnormal—Azathioprine—multiple sclerosis	0.00056	0.00453	CcSEcCtD
Carbinoxamine—Confusional state—Mitoxantrone—multiple sclerosis	0.000554	0.00448	CcSEcCtD
Carbinoxamine—Dizziness—Cladribine—multiple sclerosis	0.000553	0.00447	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000538	0.00435	CcSEcCtD
Carbinoxamine—Tachycardia—Mitoxantrone—multiple sclerosis	0.000536	0.00434	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—multiple sclerosis	0.000532	0.0043	CcSEcCtD
Carbinoxamine—Vomiting—Cladribine—multiple sclerosis	0.000532	0.0043	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000531	0.0043	CcSEcCtD
Carbinoxamine—Anorexia—Mitoxantrone—multiple sclerosis	0.000524	0.00424	CcSEcCtD
Carbinoxamine—Headache—Cladribine—multiple sclerosis	0.000524	0.00424	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisolone—multiple sclerosis	0.000521	0.00421	CcSEcCtD
Carbinoxamine—Hypotension—Mitoxantrone—multiple sclerosis	0.000514	0.00416	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000504	0.00407	CcSEcCtD
Carbinoxamine—Nausea—Cladribine—multiple sclerosis	0.000497	0.00402	CcSEcCtD
Carbinoxamine—Vertigo—Prednisolone—multiple sclerosis	0.000496	0.00402	CcSEcCtD
Carbinoxamine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000494	0.00399	CcSEcCtD
Carbinoxamine—Somnolence—Mitoxantrone—multiple sclerosis	0.000489	0.00395	CcSEcCtD
Carbinoxamine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000484	0.00391	CcSEcCtD
Carbinoxamine—Convulsion—Prednisolone—multiple sclerosis	0.000479	0.00387	CcSEcCtD
Carbinoxamine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000478	0.00387	CcSEcCtD
Carbinoxamine—Fatigue—Mitoxantrone—multiple sclerosis	0.000474	0.00383	CcSEcCtD
Carbinoxamine—Constipation—Mitoxantrone—multiple sclerosis	0.00047	0.0038	CcSEcCtD
Carbinoxamine—Diarrhoea—Azathioprine—multiple sclerosis	0.000465	0.00376	CcSEcCtD
Carbinoxamine—Vertigo—Triamcinolone—multiple sclerosis	0.000456	0.00369	CcSEcCtD
Carbinoxamine—Vertigo—Methylprednisolone—multiple sclerosis	0.000455	0.00369	CcSEcCtD
Carbinoxamine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000453	0.00366	CcSEcCtD
Carbinoxamine—Dizziness—Azathioprine—multiple sclerosis	0.00045	0.00364	CcSEcCtD
Carbinoxamine—Convulsion—Triamcinolone—multiple sclerosis	0.00044	0.00356	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisolone—multiple sclerosis	0.00044	0.00356	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.00044	0.00356	CcSEcCtD
Carbinoxamine—Convulsion—Methylprednisolone—multiple sclerosis	0.000439	0.00355	CcSEcCtD
Carbinoxamine—Urticaria—Mitoxantrone—multiple sclerosis	0.000437	0.00353	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000436	0.00353	CcSEcCtD
Carbinoxamine—Vomiting—Azathioprine—multiple sclerosis	0.000432	0.0035	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—multiple sclerosis	0.000429	0.00347	CcSEcCtD
Carbinoxamine—Headache—Azathioprine—multiple sclerosis	0.000426	0.00345	CcSEcCtD
Carbinoxamine—Confusional state—Methylprednisolone—multiple sclerosis	0.000417	0.00338	CcSEcCtD
Carbinoxamine—Vertigo—Betamethasone—multiple sclerosis	0.000414	0.00335	CcSEcCtD
Carbinoxamine—Vertigo—Dexamethasone—multiple sclerosis	0.000414	0.00335	CcSEcCtD
Carbinoxamine—Insomnia—Prednisolone—multiple sclerosis	0.000408	0.0033	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisolone—multiple sclerosis	0.000405	0.00328	CcSEcCtD
Carbinoxamine—Tachycardia—Triamcinolone—multiple sclerosis	0.000405	0.00327	CcSEcCtD
Carbinoxamine—Nausea—Azathioprine—multiple sclerosis	0.000404	0.00327	CcSEcCtD
Carbinoxamine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000404	0.00327	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000401	0.00324	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000401	0.00324	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.0004	0.00324	CcSEcCtD
Carbinoxamine—Convulsion—Betamethasone—multiple sclerosis	0.000399	0.00323	CcSEcCtD
Carbinoxamine—Convulsion—Dexamethasone—multiple sclerosis	0.000399	0.00323	CcSEcCtD
Carbinoxamine—Asthenia—Mitoxantrone—multiple sclerosis	0.000394	0.00319	CcSEcCtD
Carbinoxamine—Hypotension—Methylprednisolone—multiple sclerosis	0.000387	0.00313	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisone—multiple sclerosis	0.000378	0.00306	CcSEcCtD
Carbinoxamine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000376	0.00304	CcSEcCtD
Carbinoxamine—Insomnia—Triamcinolone—multiple sclerosis	0.000375	0.00303	CcSEcCtD
Carbinoxamine—Insomnia—Methylprednisolone—multiple sclerosis	0.000374	0.00303	CcSEcCtD
Carbinoxamine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000372	0.00301	CcSEcCtD
Carbinoxamine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000372	0.00301	CcSEcCtD
Carbinoxamine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000372	0.00301	CcSEcCtD
Carbinoxamine—Agitation—Prednisone—multiple sclerosis	0.000369	0.00299	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000368	0.00298	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000368	0.00298	CcSEcCtD
Carbinoxamine—Tachycardia—Betamethasone—multiple sclerosis	0.000367	0.00297	CcSEcCtD
Carbinoxamine—Tachycardia—Dexamethasone—multiple sclerosis	0.000367	0.00297	CcSEcCtD
Carbinoxamine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000365	0.00295	CcSEcCtD
Carbinoxamine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000364	0.00295	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000364	0.00294	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000364	0.00294	CcSEcCtD
Carbinoxamine—Vertigo—Prednisone—multiple sclerosis	0.000361	0.00292	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—multiple sclerosis	0.000359	0.00291	CcSEcCtD
Carbinoxamine—Anorexia—Betamethasone—multiple sclerosis	0.000359	0.0029	CcSEcCtD
Carbinoxamine—Anorexia—Dexamethasone—multiple sclerosis	0.000359	0.0029	CcSEcCtD
Carbinoxamine—Urticaria—Prednisolone—multiple sclerosis	0.000358	0.0029	CcSEcCtD
Carbinoxamine—Fatigue—Triamcinolone—multiple sclerosis	0.000358	0.00289	CcSEcCtD
Carbinoxamine—Fatigue—Methylprednisolone—multiple sclerosis	0.000357	0.00289	CcSEcCtD
Carbinoxamine—Hypotension—Betamethasone—multiple sclerosis	0.000352	0.00284	CcSEcCtD
Carbinoxamine—Hypotension—Dexamethasone—multiple sclerosis	0.000352	0.00284	CcSEcCtD
Carbinoxamine—Vomiting—Mitoxantrone—multiple sclerosis	0.000349	0.00283	CcSEcCtD
Carbinoxamine—Convulsion—Prednisone—multiple sclerosis	0.000348	0.00281	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—multiple sclerosis	0.000346	0.0028	CcSEcCtD
Carbinoxamine—Headache—Mitoxantrone—multiple sclerosis	0.000344	0.00279	CcSEcCtD
Carbinoxamine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000342	0.00276	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000341	0.00276	CcSEcCtD
Carbinoxamine—Insomnia—Dexamethasone—multiple sclerosis	0.00034	0.00275	CcSEcCtD
Carbinoxamine—Insomnia—Betamethasone—multiple sclerosis	0.00034	0.00275	CcSEcCtD
Carbinoxamine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000338	0.00273	CcSEcCtD
Carbinoxamine—Paraesthesia—Betamethasone—multiple sclerosis	0.000338	0.00273	CcSEcCtD
Carbinoxamine—Dyspepsia—Betamethasone—multiple sclerosis	0.000331	0.00268	CcSEcCtD
Carbinoxamine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000331	0.00268	CcSEcCtD
Carbinoxamine—Urticaria—Triamcinolone—multiple sclerosis	0.000329	0.00267	CcSEcCtD
Carbinoxamine—Urticaria—Methylprednisolone—multiple sclerosis	0.000329	0.00266	CcSEcCtD
Carbinoxamine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000327	0.00265	CcSEcCtD
Carbinoxamine—Decreased appetite—Betamethasone—multiple sclerosis	0.000327	0.00265	CcSEcCtD
Carbinoxamine—Nausea—Mitoxantrone—multiple sclerosis	0.000326	0.00264	CcSEcCtD
Carbinoxamine—Fatigue—Dexamethasone—multiple sclerosis	0.000324	0.00262	CcSEcCtD
Carbinoxamine—Fatigue—Betamethasone—multiple sclerosis	0.000324	0.00262	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisone—multiple sclerosis	0.00032	0.00259	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000317	0.00256	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—multiple sclerosis	0.000316	0.00256	CcSEcCtD
Carbinoxamine—Anorexia—Prednisone—multiple sclerosis	0.000312	0.00253	CcSEcCtD
Carbinoxamine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00031	0.00251	CcSEcCtD
Carbinoxamine—Feeling abnormal—Betamethasone—multiple sclerosis	0.00031	0.00251	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—multiple sclerosis	0.000301	0.00244	CcSEcCtD
Carbinoxamine—Urticaria—Betamethasone—multiple sclerosis	0.000299	0.00242	CcSEcCtD
Carbinoxamine—Urticaria—Dexamethasone—multiple sclerosis	0.000299	0.00242	CcSEcCtD
Carbinoxamine—Dizziness—Prednisolone—multiple sclerosis	0.000298	0.00241	CcSEcCtD
Carbinoxamine—Asthenia—Triamcinolone—multiple sclerosis	0.000298	0.00241	CcSEcCtD
Carbinoxamine—Asthenia—Methylprednisolone—multiple sclerosis	0.000297	0.0024	CcSEcCtD
Carbinoxamine—Insomnia—Prednisone—multiple sclerosis	0.000296	0.0024	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisone—multiple sclerosis	0.000294	0.00238	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—multiple sclerosis	0.000291	0.00235	CcSEcCtD
Carbinoxamine—Dyspepsia—Prednisone—multiple sclerosis	0.000288	0.00233	CcSEcCtD
Carbinoxamine—Decreased appetite—Prednisone—multiple sclerosis	0.000285	0.0023	CcSEcCtD
Carbinoxamine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000283	0.00229	CcSEcCtD
Carbinoxamine—Fatigue—Prednisone—multiple sclerosis	0.000283	0.00229	CcSEcCtD
Carbinoxamine—Headache—Prednisolone—multiple sclerosis	0.000282	0.00229	CcSEcCtD
Carbinoxamine—Constipation—Prednisone—multiple sclerosis	0.00028	0.00227	CcSEcCtD
Carbinoxamine—Confusional state—Methotrexate—multiple sclerosis	0.000276	0.00223	CcSEcCtD
Carbinoxamine—Dizziness—Triamcinolone—multiple sclerosis	0.000274	0.00222	CcSEcCtD
Carbinoxamine—Dizziness—Methylprednisolone—multiple sclerosis	0.000274	0.00221	CcSEcCtD
Carbinoxamine—Feeling abnormal—Prednisone—multiple sclerosis	0.00027	0.00218	CcSEcCtD
Carbinoxamine—Asthenia—Dexamethasone—multiple sclerosis	0.00027	0.00218	CcSEcCtD
Carbinoxamine—Asthenia—Betamethasone—multiple sclerosis	0.00027	0.00218	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000268	0.00217	CcSEcCtD
Carbinoxamine—Nausea—Prednisolone—multiple sclerosis	0.000268	0.00217	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000265	0.00214	CcSEcCtD
Carbinoxamine—Vomiting—Triamcinolone—multiple sclerosis	0.000264	0.00213	CcSEcCtD
Carbinoxamine—Vomiting—Methylprednisolone—multiple sclerosis	0.000263	0.00213	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—multiple sclerosis	0.000261	0.00211	CcSEcCtD
Carbinoxamine—Urticaria—Prednisone—multiple sclerosis	0.00026	0.00211	CcSEcCtD
Carbinoxamine—Headache—Triamcinolone—multiple sclerosis	0.00026	0.0021	CcSEcCtD
Carbinoxamine—Headache—Methylprednisolone—multiple sclerosis	0.000259	0.0021	CcSEcCtD
Carbinoxamine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000257	0.00208	CcSEcCtD
Carbinoxamine—Diarrhoea—Betamethasone—multiple sclerosis	0.000257	0.00208	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—multiple sclerosis	0.000256	0.00207	CcSEcCtD
Carbinoxamine—Dizziness—Dexamethasone—multiple sclerosis	0.000249	0.00201	CcSEcCtD
Carbinoxamine—Dizziness—Betamethasone—multiple sclerosis	0.000249	0.00201	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—multiple sclerosis	0.000248	0.002	CcSEcCtD
Carbinoxamine—Nausea—Triamcinolone—multiple sclerosis	0.000246	0.00199	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—multiple sclerosis	0.000246	0.00199	CcSEcCtD
Carbinoxamine—Nausea—Methylprednisolone—multiple sclerosis	0.000246	0.00199	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—multiple sclerosis	0.000243	0.00197	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—multiple sclerosis	0.000241	0.00195	CcSEcCtD
Carbinoxamine—Vomiting—Dexamethasone—multiple sclerosis	0.000239	0.00194	CcSEcCtD
Carbinoxamine—Vomiting—Betamethasone—multiple sclerosis	0.000239	0.00194	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—multiple sclerosis	0.000238	0.00193	CcSEcCtD
Carbinoxamine—Fatigue—Methotrexate—multiple sclerosis	0.000236	0.00191	CcSEcCtD
Carbinoxamine—Headache—Dexamethasone—multiple sclerosis	0.000236	0.00191	CcSEcCtD
Carbinoxamine—Headache—Betamethasone—multiple sclerosis	0.000236	0.00191	CcSEcCtD
Carbinoxamine—Asthenia—Prednisone—multiple sclerosis	0.000235	0.0019	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000226	0.00183	CcSEcCtD
Carbinoxamine—Diarrhoea—Prednisone—multiple sclerosis	0.000224	0.00181	CcSEcCtD
Carbinoxamine—Nausea—Betamethasone—multiple sclerosis	0.000223	0.00181	CcSEcCtD
Carbinoxamine—Nausea—Dexamethasone—multiple sclerosis	0.000223	0.00181	CcSEcCtD
Carbinoxamine—Urticaria—Methotrexate—multiple sclerosis	0.000218	0.00176	CcSEcCtD
Carbinoxamine—Dizziness—Prednisone—multiple sclerosis	0.000217	0.00175	CcSEcCtD
Carbinoxamine—Vomiting—Prednisone—multiple sclerosis	0.000208	0.00169	CcSEcCtD
Carbinoxamine—Headache—Prednisone—multiple sclerosis	0.000205	0.00166	CcSEcCtD
Carbinoxamine—Asthenia—Methotrexate—multiple sclerosis	0.000196	0.00159	CcSEcCtD
Carbinoxamine—Nausea—Prednisone—multiple sclerosis	0.000195	0.00157	CcSEcCtD
Carbinoxamine—Diarrhoea—Methotrexate—multiple sclerosis	0.000187	0.00152	CcSEcCtD
Carbinoxamine—CYP2B6—Biological oxidations—CYP24A1—multiple sclerosis	0.000183	0.00613	CbGpPWpGaD
Carbinoxamine—CYP2B6—Biological oxidations—CYP27B1—multiple sclerosis	0.000183	0.00613	CbGpPWpGaD
Carbinoxamine—Dizziness—Methotrexate—multiple sclerosis	0.000181	0.00147	CcSEcCtD
Carbinoxamine—CYP2B6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000181	0.00604	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000181	0.00604	CbGpPWpGaD
Carbinoxamine—CYP2E1—Biological oxidations—CYP24A1—multiple sclerosis	0.000179	0.006	CbGpPWpGaD
Carbinoxamine—CYP2E1—Biological oxidations—CYP27B1—multiple sclerosis	0.000179	0.006	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000177	0.00592	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000177	0.00592	CbGpPWpGaD
Carbinoxamine—Vomiting—Methotrexate—multiple sclerosis	0.000174	0.00141	CcSEcCtD
Carbinoxamine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000173	0.0058	CbGpPWpGaD
Carbinoxamine—Headache—Methotrexate—multiple sclerosis	0.000172	0.00139	CcSEcCtD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—IL4—multiple sclerosis	0.000168	0.00561	CbGpPWpGaD
Carbinoxamine—Nausea—Methotrexate—multiple sclerosis	0.000163	0.00132	CcSEcCtD
Carbinoxamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000157	0.00524	CbGpPWpGaD
Carbinoxamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000157	0.00524	CbGpPWpGaD
Carbinoxamine—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000155	0.00519	CbGpPWpGaD
Carbinoxamine—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000155	0.00519	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000153	0.00512	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000153	0.00512	CbGpPWpGaD
Carbinoxamine—HRH1—G alpha (q) signalling events—GPR65—multiple sclerosis	0.000152	0.00508	CbGpPWpGaD
Carbinoxamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000151	0.00505	CbGpPWpGaD
Carbinoxamine—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.00015	0.00504	CbGpPWpGaD
Carbinoxamine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000138	0.00463	CbGpPWpGaD
Carbinoxamine—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000138	0.00463	CbGpPWpGaD
Carbinoxamine—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000138	0.00463	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000136	0.00457	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000136	0.00457	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—multiple sclerosis	0.000136	0.00454	CbGpPWpGaD
Carbinoxamine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000127	0.00426	CbGpPWpGaD
Carbinoxamine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000127	0.00426	CbGpPWpGaD
Carbinoxamine—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000126	0.00422	CbGpPWpGaD
Carbinoxamine—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000126	0.00422	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000125	0.0042	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000125	0.0042	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.000125	0.00417	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000124	0.00416	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000124	0.00416	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.000117	0.00393	CbGpPWpGaD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—TYK2—multiple sclerosis	0.000108	0.00362	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.000107	0.00359	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.000101	0.00336	CbGpPWpGaD
Carbinoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.96e-05	0.00333	CbGpPWpGaD
Carbinoxamine—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.56e-05	0.0032	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—S1PR1—multiple sclerosis	9.5e-05	0.00318	CbGpPWpGaD
Carbinoxamine—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.37e-05	0.00313	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	9.2e-05	0.00308	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	9.2e-05	0.00308	CbGpPWpGaD
Carbinoxamine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.32e-05	0.00278	CbGpPWpGaD
Carbinoxamine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.32e-05	0.00278	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.2e-05	0.00275	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.2e-05	0.00275	CbGpPWpGaD
Carbinoxamine—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.1e-05	0.00271	CbGpPWpGaD
Carbinoxamine—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.75e-05	0.00259	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—GPR65—multiple sclerosis	7.66e-05	0.00256	CbGpPWpGaD
Carbinoxamine—CYP2E1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.59e-05	0.00254	CbGpPWpGaD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—STAT3—multiple sclerosis	7.57e-05	0.00253	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	7.36e-05	0.00246	CbGpPWpGaD
Carbinoxamine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.23e-05	0.00242	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	7.11e-05	0.00238	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CCR1—multiple sclerosis	7e-05	0.00234	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CXCL13—multiple sclerosis	7e-05	0.00234	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	6.92e-05	0.00231	CbGpPWpGaD
Carbinoxamine—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	6.91e-05	0.00231	CbGpPWpGaD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—MAPK1—multiple sclerosis	6.88e-05	0.0023	CbGpPWpGaD
Carbinoxamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.65e-05	0.00222	CbGpPWpGaD
Carbinoxamine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.59e-05	0.00221	CbGpPWpGaD
Carbinoxamine—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.56e-05	0.0022	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	6.55e-05	0.00219	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	6.38e-05	0.00214	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	6.31e-05	0.00211	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	6.09e-05	0.00204	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.95e-05	0.00199	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.95e-05	0.00199	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	5.93e-05	0.00198	CbGpPWpGaD
Carbinoxamine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.86e-05	0.00196	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	5.47e-05	0.00183	CbGpPWpGaD
Carbinoxamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.39e-05	0.0018	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—S1PR1—multiple sclerosis	5.37e-05	0.0018	CbGpPWpGaD
Carbinoxamine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.34e-05	0.00179	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.31e-05	0.00178	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.31e-05	0.00178	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CCL3—multiple sclerosis	4.99e-05	0.00167	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	4.92e-05	0.00165	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—S1PR1—multiple sclerosis	4.87e-05	0.00163	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.84e-05	0.00162	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.84e-05	0.00162	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—PTGER4—multiple sclerosis	4.8e-05	0.00161	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CXCR3—multiple sclerosis	4.64e-05	0.00155	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—RGS1—multiple sclerosis	4.56e-05	0.00153	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CCR2—multiple sclerosis	4.51e-05	0.00151	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	4.46e-05	0.00149	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—SRM—multiple sclerosis	4.44e-05	0.00149	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—SRM—multiple sclerosis	4.35e-05	0.00146	CbGpPWpGaD
Carbinoxamine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.35e-05	0.00145	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—GPR65—multiple sclerosis	4.33e-05	0.00145	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	4.24e-05	0.00142	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CNR1—multiple sclerosis	4.16e-05	0.00139	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—RGS1—multiple sclerosis	4.14e-05	0.00139	CbGpPWpGaD
Carbinoxamine—CYP2B6—Biological oxidations—POMC—multiple sclerosis	4.12e-05	0.00138	CbGpPWpGaD
Carbinoxamine—CYP2E1—Biological oxidations—POMC—multiple sclerosis	4.03e-05	0.00135	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CCR1—multiple sclerosis	3.96e-05	0.00132	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CXCL13—multiple sclerosis	3.96e-05	0.00132	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—GPR65—multiple sclerosis	3.93e-05	0.00131	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.82e-05	0.00128	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—LINGO1—multiple sclerosis	3.8e-05	0.00127	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—SRM—multiple sclerosis	3.76e-05	0.00126	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CXCL10—multiple sclerosis	3.75e-05	0.00125	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CXCL13—multiple sclerosis	3.59e-05	0.0012	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CCR1—multiple sclerosis	3.59e-05	0.0012	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	3.58e-05	0.0012	CbGpPWpGaD
Carbinoxamine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.52e-05	0.00118	CbGpPWpGaD
Carbinoxamine—CYP2C8—Biological oxidations—POMC—multiple sclerosis	3.49e-05	0.00117	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—SRM—multiple sclerosis	3.36e-05	0.00112	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TAGAP—multiple sclerosis	3.29e-05	0.0011	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CCL5—multiple sclerosis	3.23e-05	0.00108	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	3.13e-05	0.00105	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	3.13e-05	0.00105	CbGpPWpGaD
Carbinoxamine—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.11e-05	0.00104	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—SRM—multiple sclerosis	3.09e-05	0.00103	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CYP24A1—multiple sclerosis	3.07e-05	0.00103	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CYP27B1—multiple sclerosis	3.07e-05	0.00103	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—SRM—multiple sclerosis	3.06e-05	0.00102	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.98e-05	0.000999	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.92e-05	0.000977	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CCR5—multiple sclerosis	2.91e-05	0.000973	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—S1PR1—multiple sclerosis	2.88e-05	0.000964	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—GPC5—multiple sclerosis	2.86e-05	0.000958	CbGpPWpGaD
Carbinoxamine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.86e-05	0.000958	CbGpPWpGaD
Carbinoxamine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.84e-05	0.00095	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—GPC5—multiple sclerosis	2.8e-05	0.000939	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—GPC5—multiple sclerosis	2.8e-05	0.000937	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.71e-05	0.000908	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	2.65e-05	0.000887	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	2.65e-05	0.000887	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.62e-05	0.000877	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.59e-05	0.000867	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CCL3—multiple sclerosis	2.56e-05	0.000857	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CCR2—multiple sclerosis	2.55e-05	0.000853	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—PTGER4—multiple sclerosis	2.46e-05	0.000825	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—RGS1—multiple sclerosis	2.45e-05	0.000819	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.42e-05	0.000811	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CXCR3—multiple sclerosis	2.38e-05	0.000797	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—RRM1—multiple sclerosis	2.37e-05	0.000794	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.37e-05	0.000792	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.37e-05	0.000792	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CNR1—multiple sclerosis	2.35e-05	0.000788	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—RRM1—multiple sclerosis	2.32e-05	0.000778	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—GPR65—multiple sclerosis	2.32e-05	0.000777	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CCR2—multiple sclerosis	2.32e-05	0.000775	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.31e-05	0.000774	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	2.28e-05	0.000763	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—POMC—multiple sclerosis	2.27e-05	0.000761	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—CCL2—multiple sclerosis	2.22e-05	0.000744	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.18e-05	0.000728	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.18e-05	0.000728	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.16e-05	0.000724	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.16e-05	0.000722	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.16e-05	0.000722	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CNR1—multiple sclerosis	2.14e-05	0.000715	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CXCL13—multiple sclerosis	2.12e-05	0.00071	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCR1—multiple sclerosis	2.12e-05	0.00071	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.12e-05	0.000709	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.11e-05	0.000706	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—SRM—multiple sclerosis	2.02e-05	0.000676	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—RRM1—multiple sclerosis	2.01e-05	0.000672	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.99e-05	0.000666	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.97e-05	0.00066	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CXCL10—multiple sclerosis	1.92e-05	0.000644	CbGpPWpGaD
Carbinoxamine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.87e-05	0.000626	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CCL5—multiple sclerosis	1.82e-05	0.00061	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.79e-05	0.0006	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.75e-05	0.000586	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CCL5—multiple sclerosis	1.66e-05	0.000554	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.65e-05	0.000552	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—CCR5—multiple sclerosis	1.64e-05	0.00055	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.63e-05	0.000547	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.62e-05	0.000542	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.56e-05	0.000522	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCL3—multiple sclerosis	1.51e-05	0.000506	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CCR5—multiple sclerosis	1.49e-05	0.000499	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL2RA—multiple sclerosis	1.47e-05	0.000492	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PTGER4—multiple sclerosis	1.46e-05	0.000487	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—PGR—multiple sclerosis	1.43e-05	0.00048	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.42e-05	0.000476	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.42e-05	0.000476	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CXCR3—multiple sclerosis	1.41e-05	0.000471	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CD28—multiple sclerosis	1.39e-05	0.000466	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.39e-05	0.000466	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCR2—multiple sclerosis	1.37e-05	0.000458	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.36e-05	0.000456	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.34e-05	0.000448	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—BCHE—multiple sclerosis	1.33e-05	0.000447	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.3e-05	0.000435	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—POMC—multiple sclerosis	1.28e-05	0.00043	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.27e-05	0.000425	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CNR1—multiple sclerosis	1.26e-05	0.000423	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.22e-05	0.000409	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.2e-05	0.0004	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—POMC—multiple sclerosis	1.17e-05	0.00039	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.15e-05	0.000386	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—CCL2—multiple sclerosis	1.14e-05	0.000382	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CXCL10—multiple sclerosis	1.14e-05	0.00038	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.09e-05	0.000365	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.09e-05	0.000365	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.08e-05	0.000361	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—TYK2—multiple sclerosis	1.04e-05	0.000347	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.03e-05	0.000345	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CD86—multiple sclerosis	9.94e-06	0.000333	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.93e-06	0.000332	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCL5—multiple sclerosis	9.78e-06	0.000327	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—IL2—multiple sclerosis	9.49e-06	0.000318	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.47e-06	0.000317	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.39e-06	0.000314	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—SPP1—multiple sclerosis	9.06e-06	0.000303	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCR5—multiple sclerosis	8.81e-06	0.000295	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL2RA—multiple sclerosis	8.69e-06	0.000291	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL2—multiple sclerosis	8.62e-06	0.000289	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—APOE—multiple sclerosis	8.2e-06	0.000274	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—APOE—multiple sclerosis	8.03e-06	0.000269	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—APOE—multiple sclerosis	8.02e-06	0.000268	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CD80—multiple sclerosis	7.25e-06	0.000243	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—POMC—multiple sclerosis	7.04e-06	0.000236	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—APOE—multiple sclerosis	6.94e-06	0.000232	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—POMC—multiple sclerosis	6.9e-06	0.000231	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—POMC—multiple sclerosis	6.89e-06	0.000231	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—CCL2—multiple sclerosis	6.74e-06	0.000226	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—MAPK1—multiple sclerosis	6.6e-06	0.000221	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ALB—multiple sclerosis	6.42e-06	0.000215	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ALB—multiple sclerosis	6.29e-06	0.00021	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—APOE—multiple sclerosis	6.2e-06	0.000207	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.19e-06	0.000207	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TYK2—multiple sclerosis	6.12e-06	0.000205	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—POMC—multiple sclerosis	5.96e-06	0.0002	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—APOE—multiple sclerosis	5.7e-06	0.000191	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—APOE—multiple sclerosis	5.65e-06	0.000189	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ALB—multiple sclerosis	5.44e-06	0.000182	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—POMC—multiple sclerosis	5.32e-06	0.000178	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL2—multiple sclerosis	5.09e-06	0.00017	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—IL6—multiple sclerosis	5.07e-06	0.00017	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—POMC—multiple sclerosis	4.89e-06	0.000164	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—POMC—multiple sclerosis	4.85e-06	0.000162	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ALB—multiple sclerosis	4.85e-06	0.000162	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MMP9—multiple sclerosis	4.82e-06	0.000161	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ALB—multiple sclerosis	4.46e-06	0.000149	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ALB—multiple sclerosis	4.42e-06	0.000148	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—STAT3—multiple sclerosis	4.29e-06	0.000143	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MYC—multiple sclerosis	3.98e-06	0.000133	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—TGFB1—multiple sclerosis	3.97e-06	0.000133	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—MAPK1—multiple sclerosis	3.9e-06	0.00013	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—APOE—multiple sclerosis	3.73e-06	0.000125	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—POMC—multiple sclerosis	3.2e-06	0.000107	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—IL6—multiple sclerosis	2.99e-06	0.0001	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ALB—multiple sclerosis	2.92e-06	9.76e-05	CbGpPWpGaD
